Short answer
Bicara Therapeutics Inc. (BCAX) filed an 8-K current report with the SEC on May 21, 2026 reporting Item 8.01 (Other Events). Bicara reported three-year overall survival and deep responses for ficerafusp alfa plus pembrolizumab.
Bicara Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Bicara reported three-year overall survival and deep responses for ficerafusp alfa plus pembrolizumab
- Data address first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma
- Results support TGF-β inhibition as a potential treatment differentiator
- Full efficacy details and clinical context provided in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bicara Therapeutics Inc. 8-K filings
Get the next BCAX 8-K as it lands
Follow BCAX for push alerts, or ask the research agent what this filing means.